Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian T Tsuji

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|March 10, 2010
Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic modelJürgen B Bulitta, Jenny C Yang, Liliana Yohonn, et al.
International Journal of Antimicrobial Agents|December 10, 2016
In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection modelRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Journal of Pharmaceutical Sciences|October 25, 2023
Distinguishing Inducible and Non-Inducible Resistance to Colistin in Pseudomonas aeruginosa by Quantitative and Systems Pharmacology Modeling at Low and Standard InoculaJürgen B Bulitta, Eunjeong Shin, Phillip J Bergen, et al.
Antimicrobial Agents and Chemotherapy|January 6, 2016
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor CombinationsRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2016
Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosaNeang S Ly, Zackery P Bulman, Jürgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bacteremiaMotoyasu Miyazaki, Tohru Takata, Hisae Yoshimura, et al.
Infectious Diseases and Therapy|December 10, 2015
Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaPhillip J Bergen, Zackery P Bulman, Cornelia B Landersdorfer, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2015
Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin ExposureJustin R Lenhard, Tanya Brown, Michael J Rybak, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2017
Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coliNicholas M Smith, Zackery P Bulman, Arthur O Sieron, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2012
Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureusBrian T Tsuji, Tanya Brown, Ridhi Parasrampuria, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|March 10, 2010
Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic modelJürgen B Bulitta, Jenny C Yang, Liliana Yohonn, et al.
International Journal of Antimicrobial Agents|December 10, 2016
In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection modelRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Journal of Pharmaceutical Sciences|October 25, 2023
Distinguishing Inducible and Non-Inducible Resistance to Colistin in Pseudomonas aeruginosa by Quantitative and Systems Pharmacology Modeling at Low and Standard InoculaJürgen B Bulitta, Eunjeong Shin, Phillip J Bergen, et al.
Antimicrobial Agents and Chemotherapy|January 6, 2016
Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor CombinationsRachel L Soon, Justin R Lenhard, Zackery P Bulman, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2016
Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosaNeang S Ly, Zackery P Bulman, Jürgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy|February 2, 2011
Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bacteremiaMotoyasu Miyazaki, Tohru Takata, Hisae Yoshimura, et al.
Infectious Diseases and Therapy|December 10, 2015
Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaPhillip J Bergen, Zackery P Bulman, Cornelia B Landersdorfer, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2015
Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin ExposureJustin R Lenhard, Tanya Brown, Michael J Rybak, et al.
The Journal of Antimicrobial Chemotherapy|May 16, 2017
Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coliNicholas M Smith, Zackery P Bulman, Arthur O Sieron, et al.
Antimicrobial Agents and Chemotherapy|April 25, 2012
Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureusBrian T Tsuji, Tanya Brown, Ridhi Parasrampuria, et al.
Pageof 11